Link, Hartmut; Illerhaus, G.; Martens, U.M.; Salar Silvestre, Antonio; Depenbusch, R.; Köhler, A.; Engelhardt, M.; Mahlmann, S.; Zaiss, M.; Lammerich, A.; Bias, P.; Buchner, A.
(SpringerOpen, 2021)
Background: Lipegfilgrastim has been shown to be non-inferior to pegfilgrastim for reduction of the duration of severe neutropenia (DSN) in breast cancer patients. This open-label, non-inferiority study assessed the efficacy ...